Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Q4 2024 Earnings Presentation
15 slides from Optomed Oyj Class A's earnings presentation, Feb 13, 2025
Slide 1: Optomed Q4 2024
Optomed Q4 2024 13th February 2025 Juho Himberg, CEO Sakari Knuutti, CFO
Slide 2: Highlights Q4
Highlights Q4 1. 2. 3. Devices segment Software Segment Positive cashflow from revenue surged declined slightly operating activities by almost 150% and strong cash supported by the position at the US deal year end
Slide 3: Q4-2024 Key Figures
Q4-2024 Key Figures STRONG QUARTER OVERALL Q4/2024 Q4/2023 Change Revenue 5,099 3,660 39.3% Gross profit 3,321 2,489 33.4% Gross margin 65.1% 68.0% -29pps Adjusted EBITDA -532 -757 29.7% Adjusted EBITDA margin -10,4% -20,7% +103pps Net profit / loss -989 -1,530 35.3% Earnings per share -0.05 -0.09 4
Slide 4: 2024 Key Figures
2024 Key Figures THE FULL YEAR REVENUE REMAINED ON THE SAME LEVEL DUE TO WEAKER Q2 AND Q3 2024 2023 Change Revenue 15,040 15,100 -0.4% Gross profit 9,676 10,292 -6.0% Gross margin 64.3% 68.2% -38pps Adjusted EBITDA -2,796 -1,470 -90.2% Adjusted EBITDA margin -18.6% -9.7% -89pps Net profit / loss -5,
Slide 5: Segment highlights
Segment highlights OPT@MED
Slide 6: Devices Segment Q4-2024
Devices Segment Q4-2024 OUR TOPLINE GREW 149.3 % Q4/2024 Q4/2023 Change Revenue surged as the Devices segment 1. received a large order from the US Revenue 2,551 1,023 149.3% The timing and size of large deals Gross profit 1,476 590 150.2% 2. remains hard to forecast Gross margin 57.9% 57.7% +2pps G
Slide 7: Software Segment Q4-2024
Software Segment Q4-2024 SOFTWARE REVENUE DECLINED SLIGHTLY Q4/2024 Q4/2023 Change Revenue 2,549 2,637 -3.3% Software segment revenue declined 1. slightly mainly due to slower-than- expected contract renewals Gross profit 1,845 1,899 -2.8% We anticipate a recovery in 2025 Gross margin 72.4 % 72.0 %
Slide 8: Cash Flow Q4-2024
Cash Flow Q4-2024 CASH POSITION AT EUR 10.5 MILLION Q4 2024 Q4 2023 Loss for the financial year -989 -1,530 Cash flows before change • Positive net cash from operating in net working capital -349 -835 activities Change in net working capital 690 434 • The Chinese credit loss Cash flows before financ
Slide 9: Outlook 2025
Outlook 2025 Key items supporting our growth: • Increased adoption of AI-powered screening solutions, particularly in the U.S. following the FDA clearance • New partnerships and collaborations with Outlook 2025: healthcare providers and research institutions • Continued innovation and investment in
Slide 10: Summary
Summary • Strong finish for the year 2024 • Strong growth expected in 2025 • External reporting changes are under review and a CMD will be arranged in the Fall at the earliest • Optomed remains committed to its mission of making eye screening accessible and efficient worldwide
Slide 11: Appendix
Appendix OPT@MED
Slide 12: Devices Segment 2024
Devices Segment 2024 2024 2023 Change Revenue 5,326 5,009 6.3% Gross profit 2,778 2,947 -5.7% Gross margin 52.2% 58.8% -67pps EBITDA -1,673 -1,264 -32.4% EBITDA margin -31.4% -25.2% -62pps
Slide 13: Software Segment 2024
Software Segment 2024 2024 2023 Change Revenue 9,714 10,091 -3.7% Gross profit 6,889 7,346 -6.2% Gross margin 70.9% 72.8% -19pps EBITDA 1,897 2,629 -27.8% EBITDA margin 19.5% 26.1% -65pps
Slide 14: Cash Flow 2024
Cash Flow 2024 2024 2023 Loss for the financial year -5,450 -4,441 Cash flows before change in net working capital -2,764 -1,491 Change in net working capital 1,254 1,137 Cash flows before finance items -1,510 -354 Cash flows from finance items -85 -262 Net cash from operating activities -1,596 -615
Slide 15: Balance Sheet
Balance Sheet 31 December 2024 31 December 2023 • Equity ratio of 74.4 (70.0) ASSETS percent Goodwill 4,256 4,256 Development costs 8,288 7,731 Other intangible assets 1,421 1,759 • Total borrowings of EUR Total intangible assets 13,965 13,746 2.3 (3.4) million Total tangible assets 652 710 Total no